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Neurodegenerative diseases can occur so early as to
affect neurodevelopment. From a cohort of more
than 2,000 consanguineous families with childhood
neurological disease, we identified a founder muta-
tion in four independent pedigrees in cleavage and
polyadenylation factor I subunit 1 (CLP1). CLP1 is a
multifunctional kinase implicated in tRNA, mRNA,
and siRNA maturation. Kinase activity of the CLP1
mutant protein was defective, and the tRNA endonu-
clease complex (TSEN) was destabilized, resulting in
impaired pre-tRNA cleavage. Germline clp1 null ze-
brafish showed cerebellar neurodegeneration that
was rescued by wild-type, but not mutant, human
CLP1 expression. Patient-derived induced neurons
displayed both depletion of mature tRNAs and accu-
mulation of unspliced pre-tRNAs. Transfection of
partially processed tRNA fragments into patient cells
exacerbated an oxidative stress-induced reduction
in cell survival. Our data link tRNA maturation
to neuronal development and neurodegeneration
through defective CLP1 function in humans.INTRODUCTION
tRNAs are abundantly expressed RNA molecules required to
bring amino acids to the translating ribosome for protein synthe-
sis. Of the 506 known human tRNAs, 32 are encoded as pre-
tRNAs, containing introns that are spliced during maturation
(Lowe and Eddy, 1997; Phizicky and Hopper, 2010). The nu-
clear-localized tRNA splicing endonuclease (TSEN) complex
recognizes the secondary structure of pre-tRNA molecules and
cleaves at the exon-intron boundaries to yield a 20,30-cyclic
phosphate (i.e., phosphodiester) and 50-OH terminal at the splice
site (Peebles et al., 1983). Although still the subject of some
debate, there are at least two proposed mechanisms of religat-
ing these ‘‘half’’ tRNAs in mammals (i.e., the 50 and 30 exons re-
maining after excision of the single intron). In the first, HSPC117
directly mediates the ligation of these ends, utilizing the phos-
phate from the phosphodiester bond in the linkage, and is in-
hibited by the presence of a 50 phosphorylation (Popow et al.,
2011). In the second, 50 phosphorylation by CLP1, a component
of the TSEN complex in mammals, is required (Paushkin et al.,
2004; Weitzer and Martinez, 2007; Zillmann et al., 1991), but
the ligase that follows has not yet been discovered. Utilization
of both pathways in human cells is documented, but their relative
importance and functional redundancy in development and
homeostasis remain unclear.Cell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc. 651
Pontocerebellar hypoplasia represents a group of inherited
progressive neurodegenerative disorders with prenatal onset,
thus intersecting development with degeneration. All subtypes
share common structural defects of the pons and cerebellum,
evident upon brain imaging. Targeted therapy is nonexistent,
and most patients die during infancy (Namavar et al., 2011b).
Mutations in any of three subunits of the TSEN complex, the
mitochondrial arginyl-tRNA synthetase gene, the RNA exosome
component EXOSC3, and the vaccine-related kinase, are found
in some cases (Budde et al., 2008; Edvardson et al., 2007;
Renbaum et al., 2009; Wan et al., 2012). We recently impli-
cated AMPD2 in PCH, causing a defect in protein translation
due to guanosine triphosphate depletion (Akizu et al., 2013).
The data implicate RNA maturation and protein synthesis
defects in PCH but also suggest that further causes are yet to
be identified.
Here, we demonstrate a requirement for CLP1 in human brain
development. We identify four independent families carrying a
founder p.R140H mutation, which impairs affinity for the TSEN
complex, kinase activity in a recombinant assay, and function
in vivo. Consistent with its role in tRNA splicing, we find depleted
mature tRNAs and excessive pre-tRNAs accumulating in pa-
tient-derived induced neurons (iNeurons). We demonstrate
sensitivity of patient cells to oxidative-stress-induced death
exacerbated by the addition of unphosphorylated 30-tRNA-
exon halves and partially corrected with 50-phospho- 30-tRNA
exon addition. In sum, we uncover an evolutionarily conserved
requirement for CLP1 during vertebrate neurogenesis and
show that CLP1 is necessary for tRNA maturation, the loss of
which leads to stress-induced cell death.
RESULTS
Patients Harboring CLP1 Mutation Have Progressive
Brain Atrophy
We collaboratively recruited more than 2,000 families, most with
documented parental consanguinity, presenting a child with
neurological disease. We performed exome sequencing on at
least one affected member per family and then analyzed each
for potentially deleterious homozygous mutations. Genome
Analysis Toolkit (GATK) (DePristo et al., 2011) was used for
variant identification and intersected with identity-by-descent
blocks from HomozygosityMapper (Seelow et al., 2009). Rare
potentially deleterious variants were prioritized against our
cumulative in-house 4,000 patient exome database and across
publicly available exome datasets, cumulatively numbering
over 10,000 individuals. From this analysis, four independent
consanguineous Turkish families with a neurodevelopmental/
neurodegenerative disorder emerged (Figure 1A), all dis-
playing an identical homozygous Chr11:57427367G>A (hg19)
single-nucleotide transition in the CLP1 gene, resulting in a
p.ARG140HIS (p.R140H) amino acid substitution mutation.
Following the identification of the mutation, it became clear
that the patients shared many clinical features, but it would
have been difficult to separate them clinically from the rest of
the cohort. After an unremarkable perinatal history, onset of
slow, progressive, neurodegenerative features and/or static
encephalopathy ensued by 6 months of age. Clinical features652 Cell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc.included failure to develop gross or fine motor skills, absent
or delayed speech, progressive spasticity, and spontaneous
epileptic seizures (Table 1 and Table S1 available online). Brain
MRI demonstrated mild atrophy of the cerebellum, pons, and
corpus callosum (Figure 1B), together with progressive micro-
cephaly. Electromyography, although initially normal at a young
age, demonstrated age-dependent muscle fibrillations and high-
amplitude motor unit potentials in one patient, indicating pro-
gressive spinal motor neuron loss. Extensive testing for known
metabolic or degenerative diseases was negative, suggesting
a heretofore unknown condition.
The mutant allele was observed heterozygous twice in unre-
lated unaffecteds in our in-house exome database of collectively
more than 2,000 independent exomes (including1,000 Turkish
individuals) and was not reported in any public database,
suggesting a carrier frequency of 1:1,000. In all families, we
confirmed that the mutation occurred within a homozygous
haplotype block (Figure S1A), suggesting a founder mutation.
The mutated amino acid residue was highly conserved in all
multicellular organisms (Figure 1C) and was predicted to be
damaging (Adzhubei et al., 2010). No other potentially delete-
rious rare homozygous CLP1 variants were present in the
database. Comparison of exome allele calls among families sug-
gested a minimal shared haplotype between Chr11:57317640–
57461472 or 143,832 bp (Figure S1B), dated to a common
ancestor 16.2 generations in the past (± 8.7 generations, see
Experimental Procedures), during the height of the Ottoman
expansion.
Direct Sanger sequence analysis of all available family mem-
bers, including deceased member 1810-VI-2 (from dried umbili-
cal cord), demonstrated segregation according to a strict
recessive mode of inheritance (Figure S1C), which was consis-
tent with pathogenesis. Obligate carriers were entirely normal.
We further found no other CLP1 mutations in any other patient
in our collective cohorts with overlapping clinical features nor
any from an additional directly sequenced cohort of 100 cases
with familial motor neuron disease.
CLP1R140H Is Functionally Compromised
To determine whether the mutation was predicted to disrupt
protein function, we modeled human CLP1 using the structure
of the partially crystallized yeast nucleotide-bound Clp1 (Noble
et al., 2007). In yeast, the p.140ARG is substituted for a LYS
at the cognate position, which is also a polar basic residue
(p.149LYS). Structure shows that the yeast p.149LYS is involved
in the formation of an inferred hydrogen bond with the highly
conserved p.59GLU residue (Figure 2A). This polar contact is
predicted to be maintained in human but disrupted in the pres-
ence of the mutant p.140HIS residue, suggesting an alteration
in protein structure or function. We found comparable CLP1 pro-
tein levels among all genotypes in primary fibroblast lysates
derived from skin biopsy (Figure 2B), suggesting that protein sta-
bility was unaltered in the presence of the mutation.
The p.R140H mutation occurred right after the ATP-binding P
loop (i.e., Walker A motif), conserved in all kinases. To determine
whether the mutation alters CLP1 kinase activity, we tested re-
combinant wild-type (WT) and mutant GST-tagged human
CLP1 protein against a poly(A) RNA oligonucleotide natural
A C
B
Figure 1. Identification of a Homozygous CLP1 p.R140H Mutation in Families with Degeneration/Hypoplasia of the Central Nervous
System
(A) Pedigrees of four consanguineous Turkish families. Filled symbols, affecteds; hash, deceased; double bar, consanguinity; dashed double bar, history of
consanguinity but ancestry not established.
(B) Midline sagittal (top) and coronal (bottom) brain MRI of control compared with patients from each family showing ventriculomegaly due to atrophy. Red
arrowhead: hypoplastic/atrophic pons. White arrowhead: cerebellar folia atrophy. Double white arrowheads: hypoplastic corpus callosum. Red asterisk: fluid
cavity as a result of cerebellar atrophy (mega cisterna magna). Only axial CT was available for 1337-II-1.
(C) Stick figure of CLP1 protein and location of the p.R140H mutation near the ATP-binding P loop. Evolutionary conservation of the p.R140 residue across the
animal kingdom. NTD, N-terminal domain; P loop/Walker Amotif, Switch loop I; Switch loop II; base-binding loop, involved in nucleotide binding; CTD, C-terminal
domain. H.s., human; M.m., mouse; G.g., chicken; X.l., frog; D.m., fly; C.e., worm; S.c., yeast.
Further analysis in Figure S1.kinase substrate in an established assay (Ramirez et al., 2008).
Recombinant mutant p.R140H CLP1 was stable to purification
(Figure S2A) but displayed defective kinase activity, reduced
by more than half of WT levels (Figure 2C). We conclude that
CLP1 kinase activity was functionally impaired as a result of
the p.R140H mutation.
We found that CLP1, each of the known TSENs, and
HSPC117 were expressed ubiquitously in 14 human tissues
and ages tested (Figure S2B), suggesting a conserved function.
Therefore, to understand the selective cellular vulnerability, we
generated induced neurons (iNeurons) from affected and unaf-
fected fibroblasts, using recently published methods (Xue
et al., 2013), yielding 80% neural cells in culture (Figures
S2C–S2E). Both patient fibroblasts and iNeurons showed
reduced nuclear-localized CLP1, supported by nuclear/cyto-
plasmic fibroblast cell fractionation (Figures 2D and 2E). We
conclude that the p.R140H mutation results in both failed nu-
clear localization and impaired kinase activity as a mechanism
of impaired function.Mutant Zebrafish Phenocopy CLP1R140H Mutant
Patients
Recent work inmice suggests an essential function forClp1 even
before zygotic implantation; however, mice with a homozygous
kinase-dead mutant allele (p.K127A) survived embryogenesis
but died perinatally with spinal motor neuron degeneration (Ha-
nada et al., 2013). To test for central nervous system require-
ments in a model vertebrate, we generated a germline clp1
p.R44X mutation by ENU mutagenesis in zebrafish and bred to
homozygosity. WT fish showed strong neural clp1 expression
by in situ hybridization (ISH), which was severely reduced in
mutants (Figure S3A). Heterozygous and WT clutchmates were
indistinguishable, but homozygous mutants did not survive
past 5 days postfertilization (dpf) and displayed abnormal swim-
ming behavior, abnormal head shape, and curved tail, which is
consistent with a neuromotor defect (Figures 3A and 3B). A
second allele, representing a missense mutation near the kinase
domain (p.L35R), showed a similar uniform lethality by 5 dpf (Fig-
ure S3B). We conclude that clp1 is essential in zebrafish.Cell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc. 653
Table 1. Clinical Phenotypes
1810-VI-1
1327-IV-3 (died at
4 years old) 1327-IV-4 1327-IV-5 72597-II-1 72597-II-2 1337-II-1 1337-II-4
Evaluation gender F M F M F F M M
ethnic origin Turkish Turkish Turkish Turkish Turkish Turkish Turkish Turkish
pregnancy duration
(weeks)
40 38 NA NA 37 38 38 38
polyhydramnios   NA NA    
weight at birth (kg) 3.5 2.74 NA NA 2.48 3.10 NA NA
length at birth (cm) NA 49 NA NA 46 51 NA NA
HC at birth (SD) 2 SD 2 SD 2 SD NA 1/2 SD 0 SD 0 SD 0 SD
diagnosis age 3 years 2 years 9 months NA NA 8 years 5 years 5 years 6 years
HC at latest examination
(SD)
4 SD 9/10 SD 8 /9 SD NA 6 SD 3 SD 1/2 SD 1/2 SD
intellectual disability + + + + + + + +
irritability       + +
Seizures seizures + + (left temporal) + + + febrile (once) + 
seizure onset 3 years 50 days 2 months 2 years 3 years  2 years 3 years
Motor findings spasticity + + +    + +
jitteriness/clonus     +   
hypertonia  + + +   + +
hypotonia +    + (severe) + (severe)  
deep tendon reflexes increased increased increased increased decreased decreased increased increased
Visual findings central visual impairment  NA NA    NA +
primary optic atrophy  NA NA    NA +
nystagmus  NA NA    NA 
strabismus  NA NA    NA +
fixation and following + NA NA  +/ +/ NA +
Developmental
milestones
(normal/delayed/
absent)
gross motor delayed/absent delayed/absent delayed/absent delayed delayed/absent delayed/absent delayed delayed
fine motor absent absent absent delayed absent absent delayed delayed
language absent absent absent delayed delayed delayed absent absent
cognitive absent delayed/absent absent delayed delayed/absent delayed/absent delayed delayed
social delayed delayed delayed delayed delayed delayed delayed delayed
Diagnostic tests EMG 7 months:
unremarkable;
14 years: muscle
fibrillations
   1 year: limited study
unremarkable
  
EEG severe slow
waves of high
amplitude
left temporal
discharges
NA NA normal normal normal normal
(Continued on next page)
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.From timed larvae, whole-mount ISH for the midbrain marker,
otx2, demonstrated unremarkable expression level and distribu-
tion at 24 hr postfertilization (hpf) in mutants (Figure 3C). How-
ever, by 48 hpf, mutants displayed weak, spatially restricted
expression of otx2, and by 72 hpf, otx2 was not evident in the
mutant zebrafish. Because otx2 expression was initially
unremarkable in mutant animals, our data suggest that the pro-
gressive loss of expression results from cell loss as opposed to
defective patterning. To further differentiate between these pos-
sibilities, we performed terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) to detect DNA fragmentation
(Chen et al., 2010). We noted a dramatic increase in staining spe-
cific to the forebrain and hindbrain (Figure 3D). Therefore, clp1
mutant zebrafish showed evidence of hindbrain neurodegenera-
tion, similar to tsen54 zebrafish morphants (Kasher et al., 2011).
The similarity in brain phenotype between the human p.R140H
and the zebrafish mutations suggests loss of function as the dis-
ease mechanism in humans.
We next tested for a spinal motor neuron phenotype because
both mouse and human show loss of this class of neurons with
CLP1 mutations. Zebrafish larvae were fixed at 72 hpf and
stained with the motor neuron marker Sv2 (Boon et al., 2009).
Specifically in the clp1 p.R44X mutants, we found altered motor
neuron morphology with full penetrance (Figure S3C), similar to
established zebrafish motor neuron mutants (Fassier et al.,
2010).
In mouse, multiple phenotypes observed in Clp1 mutants are
rescued by allelic removal of Trp53, encoding p53, suggesting
that the cellular apoptosis observed in clp1 mutants may be
p53 dependent (Hanada et al., 2013). In order to test this in ze-
brafish, we performed tp53, abbreviated p53, morpholino
knockdown using a published reagent (Langheinrich et al.,
2002) in clp1 WT and mutants and then performed otx2 ISH as
a marker for cell loss. We observed rescued otx2 expression in
p53 knockdown clp1mutant zebrafish, suggesting that the neu-
ral apoptosis is p53 dependent (Figure S3D). We also performed
zygotic knockdown of the singleHSPC117 zebrafish orthologue,
rtbc, the gene proposed to mediate the redundant splicing
pathway, with either ATG- or splice-blocking morpholinos,
achieving near-complete loss of spliced transcript with the latter.
However, we found no phenotype in any of the morphants (data
not shown). We additionally performed hspc117 knockdown in
clp1 p.R44X mutants but found no exacerbation of the clp1
mutant phenotype (data not shown), suggesting that, at least in
zebrafish, it does not play an essential role or genetically interact
with clp1.
To determine whether human CLP1 is a functional orthologue
of zebrafish clp1, we injected WT and mutant human CLP1
mRNA into clp1 p.R44X mutant fish zygotes. The curved tail
phenotype was apparent by 48 hpf, so we utilized this as a
readout as measured by the depth of the vertebral curve from
highest to lowest point at 3 dpf. Average height was less than
50 mm in WT fish was but more than 300 mm in mutant fish (Fig-
ure 3E). Injection of WT humanCLP1mRNA partially rescued the
average curve height to less than 200 mm, although it was vari-
able from fish to fish. Injection of the human p.R140H mutant
CLP1 mRNA did not mediate such rescue, with peak average
height not less than 300 mm. In addition, we performed ISH forCell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc. 655
Figure 2. CLP1 p.R140H Is Stable but Functionally Compromised
(A) Homology modeling of human CLP1 with the crystal structure of yeast Clp1 (left). Bottom: magnified images of the p.140R and p.140H residues in human and
p.149K residue in yeast. Substitution predicted to disrupt conserved hydrogen bond (red arrowhead) formed between p.R140 and GLU (red arrow, residue 48 in
human and 59 in yeast).
(B) Unaltered levels of CLP1 protein from affected cells.
(C) Defective kinase activity of recombinant human CLP1 p.R140H mutation (purification shown in Figure S2) against RNA poly(A)20 and RNA SYBR staining
(bottom), quantified at right.
(D) Nuclear localization of CLP1 p.R140H is reduced in affected cells (schematic and iNeuron generation shown in Figure S2).
(E) Western blot of cellular fractions showing CLP1 mislocalization in patient fibroblasts. TFIIH, b-ACTIN, and GAPDH: loading controls, quantified below.
N, nuclear; C, cytoplasmic,; Unaff., unaffected, Aff., affected. Error bar, SEM. *p < 0.05, Student’s t test. Scale bar, 10 mm.otx2 on WT and clp1 p.R44X mutants injected with human CLP1
mRNA. As expected, human WT CLP1, but not CLP1R140H, was
sufficient to prevent most loss of otx2 expression in clp1 p.R44X
mutants (Figure 3F). We conclude that human CLP1 can at least
partially replace the zebrafish clp1, suggesting that the human
and zebrafish CLP1 genes are orthologues and that the human
mutation lacks activity in vivo.
Patient CLP1R140H iNeurons Show Intron-Containing
Pre-tRNA Accumulation and Mature tRNA Depletion
Due to the sharedhindbrain phenotypeobserved in zebrafish and
the established role of the TSEN/CLP1 complex in tRNA splicing,
we pursued defective tRNA splicing as a potential diseasemech-
anism. In order to study the relative expression of the known 32
intron-containing tRNA isoforms (i.e., genes), following reverse
transcription (RT) of total RNA, we generated isoform-specific
pre-tRNA primers to each, utilizing the unique intronic sequence
for the reverse primer (Figure 4A). Excluding those that failedPCR656 Cell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc.or where expression was undetectable, using RT-PCR, we pro-
filed the expression of the remaining 15 in human cortex, iNeur-
ons, and fibroblasts (Figure S4A). Expression in brain more
closely mirrored expression in iNeurons than fibroblasts, sup-
porting the use of iNeurons for these experiments.
To test for defective tRNA splicing, we generated cDNA from
fibroblasts and iNeurons and then analyzed expression of these
pre-tRNAs using quantitative RT-PCR (qRT-PCR) to test for dif-
ferences between affected and unaffected. Normalizing to the
unaffected fibroblasts, in the half of pre-tRNAs in which a differ-
ence was noted, the differences were roughly equally distributed
into those in which the pre-tRNA was higher in the affected and
those in which it was lower in the affected (Figures 4B and S4B).
In iNeurons, however, in which a difference in pre-tRNAs level
was noted, the majority (six of eight) showed an accumulation
of pre-tRNA in affected cells compared with unaffected (Figures
4C and S4C).We conclude that there is an accumulation of some
pre-tRNAs in CLP1 patient cells.
To exclude that the qPCR data were biased due to impaired
RT of fully modified tRNAs, we utilized Northern blotting, the
most established method for tRNA assessment, generating
probes to interrogate representative unique isoforms for pre-
tRNA for tyrosine Chr14:tRNA19 and isoleucine Chr19:tRNA10,
as well as to detect all isoacceptor (pan: all isoacceptor, i.e.,
same anticodon) for pre-tRNA and mature tRNA for tyrosine,
isoleucine, and leucine. Most probes showed some evidence
for expression in both fibroblasts and iNeurons with the excep-
tion of pre-tRNA for Chr14:tRNA19-TyrGTA, which was detect-
able only in iNeurons, run in duplicate to avoid sample loading
variability. We identified both accumulation of pre-tRNAs and
depletion of mature tRNAs specifically in patient iNeurons. Pre-
tRNA Chr14:tRNA19-TyrGTA, pre-tRNA Chr19:tRNA10-IleTAT,
pre-tRNA IleTAT (pan), and pre-tRNA LeuCAA (pan) showed
stronger bands in affected versus unaffected iNeurons (Fig-
ure 4D).We also noted an accumulation of Chr19.tRNA10-IleTAT
intron (data not shown). Correspondingly, there was a reduction
in the amounts of mature tRNAs for isoleucine and leucine, for
mature tRNA IleTAT (pan) andmature tRNA LeuCAA (pan). These
results were quantified as the percent mature tRNA or pre-tRNA
of total tRNA for each isoacceptor and demonstrate mutation-
and neural-specific changes in pre- and mature tRNA transcript
levels.
Next, we analyzed whether the alterations in pre-tRNA levels
were due to impaired TSEN-CLP1 complex formation resulting
from the CLP1 p.R140H mutation. Using an established assay
(Figure S4D) (Paushkin et al., 2004), we found reduced amounts
of the active site containing TSEN complex proteins, TSEN2
and TSEN34, copurified with double-affinity-tagged CLP1R140H,
compared to complexes purified with WT CLP1 or TSEN54 (Fig-
ures 4E and S4E). Additionally, we generated two control mu-
tants, CLP1R140A and CLP1K127A, and observed a less severe
reduction of TSEN2 and TSEN34 bound compared to
CLP1R140H, indicating that the patient substitution p.140H is
particularly damaging to TSEN complex formation (Figures 4E
and S4E) (Hanada et al., 2013). We conclude that mutant CLP1
has altered affinity for the TSEN complex.
TodeterminewhetherCLP1R140H-,CLP1R140A- andCLP1K127A-
bound protein complexes display altered endonuclease activity,
we performed an in vitro tRNA cleavage assay using the
copurified protein complexes isolated from the two-step elution
(Figure S4D) and radiolabeled tyrosine pre-tRNA with yeast
tRNA endonuclease as a positive enzymatic control (Trotta
et al., 2006). Consistent with a severe defect in TSEN complex
affinity, CLP1R140H-associated protein complexes were unable
to cleave pre-tRNA Tyr as compared to WT CLP1-purified com-
plexes at all time points analyzed (Figure 4F). As expected,
CLP1R140A and CLP1K127A copurified complexes displayed
more endonuclease activity than CLP1R140H-bound proteins but
showed less activity than WT (Figure S4F). The data suggest
that loss of the TSEN components frommutant CLP1-associated
protein complexes impairs pre-tRNA cleavage activity.
The Tyr tRNA 50-Phospho-30-Exon Fragment Protects
CLP1R104HMutant Cells from Stress-Induced Cell Death
As there are at least two proposed mechanisms of religating
‘‘half’’ tRNAs in mammals, we set out to uncover the requirementfor CLP1 in human cells. To test for altered cell viability of CLP1
mutant cells, we performed growth analysis of fibroblasts and
iNeurons under basal conditions but detected no differences
(Figures S5A and S5B). We next tested whether overexpression
of pre-tRNAs compared with mature tRNAs was toxic in patient
iNeurons in culture because iNeurons displayed an accumula-
tion of these pre-tRNAs. Using a lentiviral delivery system
expressing Chr14:tRNA19-TyrGTA or Chr19:tRNA10-IleTAT
pre- or processed tRNA (both pre isoforms accumulated by
Northern analysis in patient iNeurons), we found no difference
in viability between patient and control iNeurons 24 hr after trans-
duction (Figure S5C). We conclude that the patient iNeurons do
not show a dose-dependent toxicity to pre-tRNAs under these
conditions.
Oxidative stress can upregulate tRNA cleavage (Thompson
et al., 2008). We detected no differences in basal protein or
DNA oxidation in patient fibroblasts or iNeurons compared
with controls but noted that iNeurons showed higher basal
oxidation than fibroblasts, irrespective of genotype (Figures
S5D and S5E). Therefore, to determine whether CLP1R140H
patient cells display heightened sensitivity to oxidative-stress-
induced cell death, we performed a dose-dependent cell viability
assay using hydrogen peroxide (H2O2). As previously reported in
murine fibroblasts (Hanada et al., 2013), we found that human
CLP1R140H mutant fibroblasts and iNeurons showed compro-
mised cell survival to H2O2 at the highest 50 mM concentration,
indicating sensitivity to oxidative stress (Figures S5F and S5G).
It was recently proposed that excessive 50-half-tRNAs were
responsible for p53-dependent activation of cellular stress in
mice (Hanada et al., 2013). Therefore, we hypothesized that
inadequate CLP1 kinase activity might result in 30-half-tRNAs
that lacked a phospho group at the 50 end (Figure 5A). We
used a stress-induced viability assay to determine whether the
patient mutation affected cell survival in the presence of various
tRNA fragments, testing whether the addition of 30- or 50-half-
tRNA fragments might exacerbate the H2O2-induced phenotype
in human cells. We predicted that the substrate, but not the
product, of CLP1 modification (i.e., the unphosphorylated, but
not the phosphorylated, 30 exon) would be toxic.
We transfected control and CLP1R140Hmutant fibroblasts with
RNA oligonucleotides corresponding to the most abundantly
expressed Tyr tRNA intermediates, either in the absence or pres-
ence of H2O2, and evaluated cell viability after 24 hr (Figures 5B
and 5C). Control fibroblasts and neural progenitor cells showed
little toxicity in response to the tRNA intermediates, either in the
absence or presence of H2O2 (Figured S5H, S5I, and S5K).
Cotreatment with the 50 exon containing the terminal 20-30-cyclic
phosphodiester did not have a notable effect on survival (Fig-
ure S5H). Most strikingly, the unphosphorylated 30 exon was
the most lethal of the tRNA halves, particularly in the presence
of H2O2 (Figures 5B and S5I). Remarkably, the 5
0 phosphorylated
30 exon did not cause toxicity and, in fact, significantly improved
viability in the presence of H2O2 (Figures 5C and S5J). These
results are consistent with the model whereby the loss of the
phosphorylated 30 exon required for HSPC117-independent
tRNA ligation (and therefore production of mature tRNAs) or the
toxic hydroxyl-30-exon (incapable of further processing inmutant
cells) may contribute to the disease phenotype.Cell 157, 651–663, April 24, 2014 ª2014 Elsevier Inc. 657
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Figure 3. Zebrafish clp1R44X Homozygous Mutants Show Gross Brain Defects, Reduced Survival, and Neurodegeneration
(A) Gross morphology of WT and clp1R44X/R44X zebrafish mutants showed misshapen head, small eyes, and curved tail (arrow), suggesting neuromotor defects.
Scale bar, 500 mm.
(B) Kaplan-Meier curve showed reduced survival of clp1R44X/R44X fish (additional allele shown in Figure S3).
(C) Progressively reduced otx2 expression in developing clp1R44X/R44X zebrafish brains. Broad otx2 expression domain at 24 hpf was unremarkable in mutant
(bracket), suggesting that initial patterning was not disrupted. From 48–72 hpf, WT fish showed expression restricted to midbrain-hindbrain organizer (bracket),
whereas mutant showed weak expression, completely absent by 72 hpf (#).
(legend continued on next page)
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DISCUSSION
Our results report the effect of a CLP1 mutation in humans.
Based upon this and previously published data, we propose
that patients with a CLP1R140H founder mutation display neuro-
degeneration due to defects in tRNA splicing. Because CLP1,
in at least one capacity, associates with the TSEN complex
and because patients display features similar to PCH, we pro-
pose that the condition we describe here should be considered
an alternative form of PCH, designated as PCH type 10. The
appearance of the brain scan is very distinct from the previously
published PCH forms, does not show the ‘‘dragonfly’’ sign
(Namavar et al., 2011a), and shows equal involvement of the
hindbrain and forebrain. Further characterization of this clinical
phenotype could help better define similarities/differences from
other forms of PCH.
Although CLP1 kinase-dead mice develop progressive loss of
spinal motor neurons, mimicking the pathology of amyotrophic
lateral sclerosis, our patients showed instead a neurodegenera-
tive disease with loss of cerebellar, brainstem, and cortical vol-
ume, thinning of the corpus callosum, and loss of acquiredmotor
and cognitive skills with evidence for later loss of motor neurons.
Certain forms of PCH show coexistent spinal motor neuron
degeneration, notably PCH type I (also known as Norman’s dis-
ease), and PCH due to EXOCS3 mutations (Goutie`res et al.,
1977; Wan et al., 2012), suggesting that both hindbrain and
motor neurons may share susceptibility across the mutation
spectrum. Cerebellar Purkinje cells and spinal motor neurons
are among the largest neurons and thus likely mostmetabolically
challenged of the cells in the nervous system, but why these spe-
cific neuronal cell types are vulnerable to reduced CLP1 activity
is unclear.
The CLP1 p.R140H mutation does not destabilize the protein
but substantially impairs kinase activity, alters the nuclear local-
ization, reduces the affinity for TSEN proteins affecting tRNA
endonuclease activity, and, when expressed in Clp1 mutant ze-
brafish, fails to rescue in vivo phenotypes. In an accompanying
manuscript in this issue of Cell, Karaca et al. (2014) show similar
biochemical findings in addition to evidence of microcephaly in
Clp1 kinase-dead mice. Together, our findings support a mech-
anism by which the patient mutation impacts several of the
known functions of CLP1.
In this study, we focus on the role of CLP1 in tRNA processing
and show elevated levels of some unspliced pre-tRNAs and
depletion of some mature tRNAs for several different isoaccep-
tors, including tyrosine, isoleucine and leucine in iNeurons. This
result implies reducedprocessivity of pre-tRNAs tomature tRNAs
when CLP1 is mutated, which we predict occurs at both the pre-
tRNA cleavage step and the ligation step directly downstream of
CLP1 in the processing cascade. The presence of the HSPC117
redundant splicing pathway may account for the rescue of pro-(D) TUNEL-positive cells were increased in mutant at 48 hpf in both the hindbrain
Figure S3.
(E) Partial rescue of the clp1R44X/R44X phenotype with human WT, but not p.R140
between uninjected and injected with p.R140H mRNA, whereas WT mRNA partia
(F) In situ for otx2 in WT, clp1R44X/R44X, and clp1R44X/R44X injected with human
expression at 48 hpf in clp1 mutants, quantified at right. n >25 embryos each cocessed tRNA levels in the presence of the CLP1 mutation in
fibroblasts, although we found no phenotype upon rtcb knock-
down in fish and no genetic interaction with clp1. Thus, the rela-
tive contributions of the two tRNA splicing pathways, or others
yet undefined, will require further investigation.
A reduction in tRNA ligation results in the accumulation of
tRNA half fragments, which inhibit protein translation and cause
cell death in yeast and mammalian cells (Sobala and Hutvagner,
2013; Thompson et al., 2008; Thompson and Parker, 2009;
Yamasaki et al., 2009). The Clp1 kinase-dead mice accumulated
a 50 tRNA exon derivative fragment, but we found no evidence of
accumulation or toxicity of this fragment in human cells. Instead,
we found that unphosphorylated 30 exon (i.e., a substrate for
CLP1), but not the phosphorylated 30 exon, exacerbated toxicity.
Our findings support a required role for CLP1 in the 50 end phos-
phorylation-dependent ligation of ‘‘half’’ tRNAs in humans.
Cumulatively, we uncover a cell-type-specific requirement for
the HSPC117-independent tRNA maturation pathway in human
development, which, when perturbed, causes a new PCH-like
neurological disease.
In addition to the tRNA processing defects described here, the
combined effect of the CLP1 loss-of-function phenotypes may
be due to impaired phosphorylation of target RNA. In particular,
CLP1 functions as an siRNA kinase required for loading siRNA
onto the RISC complex (Weitzer and Martinez, 2007), and thus,
there may be other cellular effects on these pathways as a result
of the mutation. CLP1 also functions as part of a multiprotein
complex required for 30 end cleavage in pre-mRNA processing
and maturation (de Vries et al., 2000; Wickens and Gonzalez,
2004), and, not surprisingly, we observed that CLP1R140H-bound
protein complexes were depleted of mRNA 30 end processing
proteins (data not shown). Further experimentation will be
required to test whether these other cellular mechanisms con-
tribute to the disease pathogenesis in these patients.
EXPERIMENTAL PROCEDURES
Methods and any associated references are available in the Extended Exper-
imental Procedures.
Patient Recruitment
Patients were enrolled and sampled by standard practice in approved human
subject protocols at the University of California, San Diego.
Exome Sequencing
Genomic DNA was extracted and subjected to exon capture, sequencing,
variant identification, and computational filtering as previously described
(Akizu et al., 2013). See Extended Experimental Procedures for more details.
Zebrafish
Zebrafish work was performed in accordance with AMC IACUC regula-
tions. ENUmutagenesis was performed to create two independent clp1muta-
tions. Gene knockdown was performed with morpholino oligonucleotides(arrow) and the midbrain/diencephalon (double arrow), further investigated in
H CLP1, mRNA by measuring curved tail height. No difference was detected
lly recovered curved tail phenotype. p <0.01, Student’s t test. Error bar, SEM.
CLP1 mRNA. Human CLP1, but not CLP1R140H, prevented the loss of otx2
ndition. Scale bar, 100 mm.
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Figure 4. Increased Intron-Containing Pre-tRNA inCLP1Mutant Patient Cells and Loss of TSEN Complex Affinity, Resulting in Reduced Pre-
tRNA Cleavage with CLP1-Purified Complexes
(A) Schematic pre-tRNA with location of the intron, occurring one base 30 to the anticodon. Primers designed to the individual tRNA homologue exon sequence
and the unique consensus intron (red). Amplifications with the 50 primer and any of the 30 primers.
(legend continued on next page)
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Figure 5. Toxic Effects of Unprocessed 30 ‘‘Half’’ tRNA Exon in CLP1 Patient Cells
(A) Model of tRNA splicing. The pre-tRNA contains an intron (red) 1 base 30 of the anticodon. The TSEN complex excises the intron, leaving two ‘‘half’’ tRNAs, the
50 exon containing a 20-30-phosphodiester, and the 30 exon containing a hydroxyl group. CLP1 is capable of phosphorylating the 50 end of the 30 exon, then a still-
unknown ligase repairs the break.
(B and C) Control (green) and CLP1 patient cells (red) transfected with either the unphosphorylated 30-exon (30 exon) or the phosphorylated 30 exon (P-30-exon) in
the presence or absence of hydrogen peroxide. None of the conditions were adverse to control cells (shown in Figure S5), whereas patient cells showed reduced
viability to hydrogen peroxide and 30 exon transfection and improved viability upon P-30-exon transfection. *p < 0.05, two-way ANOVA. Error bar, SEM.(Gene-Tools). Lifespan analysis, in situ hybridization, TUNEL, RNA rescue, and
immunostainingwere performedwith standard protocols. Additional detail can
be found in the Extended Experimental Procedures.
tRNA Analysis
RNA from patient fibroblasts or iNeurons was used for cDNA generation and
quantitative RT-PCR of pre-tRNAs using standard methods. Northern blot
for intron-containing pre- and mature tRNAs was assessed by standard proto-
cols. Probe and primer sequences and detailed protocols are listed in the
Extended Experimental Procedures.
Cell Culture
Fibroblasts were generated from unaffected and affected skin punch
biopsies. iNeurons were generated as previously described (Xue et al.,(B and C) qRT-PCR results showed variable changes in pre-tRNA expression in a
affected), whereas most pre-tRNA transcripts from affected iNeurons were increa
shown in Figure S4.
(D) Northern blot analysis of Chr14:tRNA19-TyrGTA and Chr19:tRNA10-IleTAT pre
mature tRNA (50 exon probes) transcripts relative to U6 loading control in duplic
tested, whereas affected iNeurons show an increase in Tyr, Ile, and Leu pre-tR
Quantification below, displayed as percent mature or pre-tRNA of total tRNA.
(E) Western blot of CLP1-purified complexes showing CLP1 p.R140H, p.R140A,
(TSEN54 served as a positive control). Quantification of the amount of TSEN2 no
(F) Time course of tRNA endonuclease reactions performed on exogenous ra
complexes. Buffer served as a negative control, and yeast tRNA endonuclease
CLP1R140H-bound complexes compared withWT, quantified at left. *p < 0.05, **p
(pull-down). Error bar, SEM.2013). HEK293T, HEK293H, primary fibroblasts, neural progenitor cells, and
iNeurons were cultured using established techniques. Basal protein and
DNA oxidation and RNA transfection were performed as suggested by the
manufacturer. Cell viability assays were performed as previously described
(Carmichael et al., 1987). Details can be found in the Extended Experimental
Procedures.
CLP1 Protein Assays
Recombinant WT and mutant GST-CLP1 were purified from E. coli and tested
for kinase activity as previously described (Ramirez et al., 2008). Double-affin-
ity purification of FlagHis-CLP1 was carried out as previously described (Trotta
et al., 2006; Volta et al., 2005). Associated protein complexes were used in
tRNA endonuclease assays and analyzed by western blot. Detailed experi-
mental techniques can be found in the Extended Experimental Procedures.ffected fibroblasts (i.e., about half were increased and half were decreased in
sed (i.e., six of eight were increased). Validation and unchanged pre-tRNAs are
-tRNA (intron probes) and tRNA-TyrGTA, tRNA-IleTAT, and tRNA-LeuCAA pan
ate showed similar amounts of pre-tRNA and mature tRNA for all transcripts
NA transcripts with a corresponding reduction in processed, mature tRNA.
and p.K127A with reduced bound TSEN2 and TSEN34 compared to WT CLP1
rmalized to FlagHis-tagged protein from four independent replicates (below).
diolabeled tyrosine (Tyr) pre-tRNA with double-affinity-purified CLP1-bound
served as a positive control. Reduced endonuclease activity observed with
< 0.01, ***p < 0.001, ****p < 0.0001, Student’s t test (qPCRs) or one-way ANOVA
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Computation
CLP1mutationsweremodeled onto the crystalized yeast structurewith Phyre2
(Kelley and Sternberg, 2009). PLINK was used to create autozygosity maps
from exome sequence (Purcell et al., 2007). The age of the CLP1 p.R140H
mutation was calculated according to published methods (Fu et al., 2013).
Additional details can be found in the Extended Experimental Procedures.
Statistical Analysis
ANOVA (one or two way) or Student’s two-tailed nonpaired t tests were carried
out to determine the statistical significance of differences between samples.
p < 0.05 was considered nominally statistically significant for all tests.
ACCESSION NUMBERS
Exome sequencing data have been deposited to the database of Genotypes
and Phenotypes (dbGAP) phs000288.v1.p1. Accession numbers for se-
quences used in the study are as follows: Refseq ID human CLP1: Gene:
NM_006831.2; Protein: NP_006822.1, Yeast clp1 Q08685, Zebrafish clp1
(LOC565621): XM_688892.4, Zebrafish rtcb (hspc117): NM_213103.1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.03.049.
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